Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 1,825 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Media Clear all

Conditions: Infections, Human Immunodeficiency Virus and Tuberculosis
Interventions: GSK1349572, Placebo, Iohexol Injection, Para-aminohippurate infusion; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Drinking Behavior
Interventions: Social media messaging; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 25 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Otitis Media With Effusion in Children, Otitis Media Recurrent
Interventions: EXE844 Sterile Otic Suspension, 0.3%, Tympanostomy Tube Insertion; Drug · Procedure
Lead sponsor: Alcon Research; Industry
Eligibility: 6 Months to 12 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Allergic Rhinitis
Interventions: ASP-1001 nasal spray, Placebo for ASP-1001; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Days to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: First Episode Psychosis
Interventions: Community Campaign La CLAVE; Other
Lead sponsor: University of Southern California; Other
Eligibility: 15 Years to 65 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Granada Hills, California

Conditions: Leukemia, B-cell, Lymphoma, Hodgkins, Lymphoma, Non-hodgkins, Lymphoma, B-Cell
Interventions: Allogeneic stem cell transplant, Anti-CD19-chimeric-antigen-receptor-transduced T cells, Leukapheresis; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2024
U.S. locations: 2
States / cities: Bethesda, Maryland • Minneapolis, Minnesota

Conditions: Contrast Medium-induced Nephropathy
Interventions: LVEDP -Based hydration strategy, Standard hydration; Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Dysphonia Resulting From Vocal Fold Scarring, Age-related Dysphonia
Interventions: Azficel-T (autologous fibroblasts), Placebo; Biological · Drug
Lead sponsor: Castle Creek Biosciences, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Los Angeles, California • Stanford, California • New York, New York

Conditions: Dengue
Interventions: Cohort 1 - Group 1 JNJ High Dose, Cohort 1 - Group 2 JNJ Medium Dose, Cohort 1 - Group 2 JNJ Low Dose, Cohort 1 - Group 1/2 Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Baltimore, Maryland • Burlington, Vermont

Conditions: Secrecy Versus Disclosure Among Adolescents With Mental Illness
Interventions: Honest Open Proud (HOP); Behavioral
Lead sponsor: University of Ulm; Other
Eligibility: 13 Years to 18 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Coronary Artery Disease, Cardiovascular Diseases
Interventions: Ultravist 370Mg I/Ml Solution for Injection; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 85 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Pancreatic Cancer, Adult
Interventions: PAL-CHW-PDAC, Usual Care with Attention Control; Behavioral · Other
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Months and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Healthy
Interventions: IVX-121, IVX-241, Placebo, MF59®; Biological · Other
Lead sponsor: Icosavax, Inc.; Industry
Eligibility: 60 Years to 75 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Hollywood, Florida • Atlanta, Georgia • Omaha, Nebraska + 1 more

Conditions: HIV Infections
Interventions: GSK3640254, Dolutegravir, Lamivudine capsules, Lamivudine tablets; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: Bakersfield, California • Palm Springs, California • Denver, Colorado + 5 more

Conditions: COVID-19, Influenza A, Influenza Type B
Interventions: Panbio™ COVID-19/Flu A&B Panel; Diagnostic Test
Lead sponsor: Abbott Rapid Dx; Industry
Eligibility: 2 Years and older
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Pelham, Alabama • Brooklyn, New York

Conditions: Dietary Guidelines
Interventions: Perception of information source; Other
Lead sponsor: USDA Grand Forks Human Nutrition Research Center; Federal
Eligibility: 18 Years to 99 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Grand Forks, North Dakota

Conditions: Seasonal Allergic Rhinitis
Interventions: bepotastine besilate nasal product - low dose, bepotastine besilate nasal product - medium dose, bepotastine besilate nasal product - high dose, placebo comparator nasal product; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Irvine, California

Conditions: Childhood Disruptive Behavior Problems
Interventions: Triple P Media Series -- Standard "Information-Only" version, Triple P Media Series -- Enhanced "Behavior Activation" version; Behavioral
Lead sponsor: Oregon Research Institute; Other
Eligibility: 20 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Non-syndromic Retinitis Pigmentosa
Interventions: Gene therapy: GS030-DP AND Medical device: GS030-MD; Combination Product
Lead sponsor: GenSight Biologics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Intimate Partner Violence (IPV)
Interventions: Condition 1: Perpetrator Positive, Condition 2: Perpetrator Negative, Condition 3: Placebo; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 4
States / cities: New Haven, Connecticut • New Orleans, Louisiana • East Lansing, Michigan + 1 more

Conditions: Bacterial Infection
Interventions: Iohexol; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 10
States / cities: Torrance, California • Detroit, Michigan • Royal Oak, Michigan + 6 more

Conditions: Migraine
Interventions: Stage 1: Naltrexone/Acetaminophen, Stage 1: Naltrexone, Stage 1: Acetaminophen, Stage1: Placebo, Stage 2: Naltrxone/Acetaminophen high dose, Stage 2: Naltrexone/Acetaminophen medium dose, Stage 2: Naltrxone/Acetaminophen low dose, Stage 2: Placebo; Drug
Lead sponsor: Allodynic Therapeutics, Inc; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: North Miami, Florida

Conditions: Postpartum Depression, Perinatal Depression
Interventions: Maternal Mental Health Access for Postpartum Depression- Prevention and UPLIFT- intervention, On-Demand + Discussion board (DB), Arm 2, On Demand (OD) + Video Conference (VC), Arm 3; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: ART
Interventions: ZyMot Multi Sperm Separation Device (850 ul), Density Gradient Centrifugation; Device · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects

Social Media Intervention for Risky Drinking

Pediatric Pharmacokinetic (PK) Study of EXE844 Otic Suspension in Otitis Media at the Time of Tympanostomy Tube Insertion (OMTT)

Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)

Reducing the Duration of Untreated Psychosis

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

Prevention of Contrast Renal Injury With Different Hydration Strategies

Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for Vocal Fold Scarring and Age-Related Dysphonia

An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge

Honest Open Proud for Adolescents With Mental Illness

VOLtage-based Contrast Media AdaptatioN in Coronary Computed Tomography Angiography

To Evaluate the Preliminary Efficacy of Our Digitally Enhanced CHW-led Intervention in Newly Diagnosed PDAC

Safety and Immunogenicity of IVX-A12 in Healthy Older Adults

A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel to Support Home Use

Survey of Diet and Health Beliefs

Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product After Ragweed Pollen Exposure in an Environmental Chamber

Evaluation of a Video-Based Media Series to Promote Effective Parenting

Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa

The Development of a Domestic Violence Perpetrator Collusion Measurement Tool

Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)

Single-Site Study of Naltrexone/Acetaminophen for the Acute Treatment of Migraine: A Phase 2 Randomized Trial

Maternal Mental Health Access - MaMa

A Sibling Oocyte Study- Comparison of ZyMotTM Microfluidics Device to Density Gradient for Sperm Selection During ICSI